Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that QSPR models effectively predict drug skin penetration, with the Potts-Guy model showing the highest predictive accuracy for the drugs tested.

This study found that norethindrone and levonorgestrel affected Arabidopsis thaliana root growth differently depending on concentration, with levonorgestrel being highly active and most effective at promoting taproot growth at low doses.

Hidradenitis suppurativa improves with antiandrogen therapy.

This review examines androgen status in male and female obesity and its influence on the metabolic syndrome, but reports no new clinical results.

This review discusses the main features of anti-androgen drugs, combined treatments, and insulin sensitizers in managing hirsutism and reports no new research findings.

This article discusses the mechanisms of hirsutism and acne in women, highlighting cyproterone acetate with ethinyloestradiol as an effective anti-androgen therapy in the UK, but it reports no new clinical findings.

This study found that both spironolactone with Ovysmen and cyproterone acetate with ethinyloestradiol significantly reduced hair growth in hirsute women, with no difference in effect between treatments.

In this study, hirsute women treated with cyproterone acetate and ethinyloestradiol experienced significant reductions in sebum secretion and hair growth after several months.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

This review examines the epidemiology, pathophysiology, diagnosis, and management strategies for non-classic congenital hyperplasia due to 21-hydroxylase deficiency, and provides evidence-based recommendations for its treatment and genetic counseling.

This study found that ethinylestradiol and high-dose cyproterone acetate significantly reduced hirsutism scores and were effective for treating acne and alopecia in women with hyperandrogenism.

This review discusses developments in oral contraceptives, highlighting improved individualization, reduced side effects, and enhanced suitability for various women's health needs, but it reports no new clinical results.

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

In this study, low doses of cyproterone acetate with ethinylestradiol were as effective as low-dose flutamide in reducing acne severity in hyperandrogenic women, while finasteride was less effective.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This study found that cyproterone acetate, given with ethinyl oestradiol, significantly reduced hirsutism in women after 12 months, although improvements reversed once cyproterone acetate was stopped.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

This study found that women with common baldness treated with cyclical antiandrogen therapy for 52 weeks experienced increased hair density and a higher percentage of hairs in the anagen growth phase.

This study found that women with androgenetic alopecia and alopecia areata had significantly lower serum ferritin levels compared to women without hair loss.

This review found moderate to very low-quality evidence that spironolactone, flutamide, and cyproterone acetate combined with oral contraceptives may reduce hirsutism more effectively than placebo or metformin, though results vary among other treatments.

This study found that in Chinese women with PCOS, pretreatment with ethinylestradiol/cyproterone acetate was associated with a lower risk of gestational diabetes, pregnancy-induced hypertension, and premature delivery compared to those without pretreatment.

This study observed that most hirsute patients on combined cyproterone acetate and 'Diane' therapy experienced a reduction in hair growth, with hair becoming softer, thinner, and lighter in color over 12 months.

This study found that while ethinyl oestradiol and cyproterone acetate effectively treated hirsutism in 90% of patients, 80% experienced relapse within six months after stopping treatment, suggesting long-term use is necessary.

A combined drug and laser treatment improved hirsutism in a PCOS patient, also enhancing her heart health and requiring regular liver and kidney checks.

This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

In this study, Diane was reported to effectively treat acne, seborrhoea, androgenic alopecia, and mild hirsutism in hirsute women, with its effectiveness influenced by the severity and duration of the condition.

This review discusses the use of ethinylestradiol combined with antiandrogenic progestin for treating androgenisation symptoms and improving metabolic and menstrual health in women, but it does not provide new clinical data.

This review evaluates therapies for hyperandrogenism, highlighting cyproterone acetate as the preferred treatment due to its potency and tolerability in managing symptoms in women.

This study found that cyproterone acetate significantly reduced both serum 3α-AdiolG levels and hirsutism scores in women with idiopathic hirsutism, PCOS, or 21-hydroxylase deficiency, suggesting its effectiveness in treating excessive hair growth.

This study observed a strong overall reduction in the use of CPA/EE in the Netherlands, despite similar proportions of users with acne or other hyperandrogenic conditions before and after the referral procedure.